Failure of chemotherapy to prolong life in patients with metastatic prostate cancer who have failed androgen deprivation

David Hickey; John Cant; Mark S. Soloway

doi:10.1016/0090-4295(88)90569-9

Failure of chemotherapy to prolong life in patients with metastatic prostate cancer who have failed androgen deprivation

David Hickey, John Cant, Mark S. Soloway

Urology

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Using historical controls, we analyzed the effect of chemotherapy on survival of patients with metastatic prostate cancer who failed androgen deprivation. The survival of 178 patients with metastatic prostate cancer who receive palliation only after failing hormonal therapy was compared with the survival of 27 patients who received chemotherapy on NPCP Protocol 1500. Survival was measured from the initiation of androgen deprivation. The mean survival after chemotherapy was 8.4 months which was slightly less than the group receiving palliation only. At this time, chemotherapy has not been able to improve survival in patients with metastatic prostate cancer.

Original language	English (US)
Pages (from-to)	38-40
Number of pages	3
Journal	Urology
Volume	31
Issue number	1
DOIs	https://doi.org/10.1016/0090-4295(88)90569-9
State	Published - Jan 1988

ASJC Scopus subject areas

Urology

Access to Document

10.1016/0090-4295(88)90569-9

Fingerprint Dive into the research topics of 'Failure of chemotherapy to prolong life in patients with metastatic prostate cancer who have failed androgen deprivation'. Together they form a unique fingerprint.

Cite this

@article{b0f55fd4dea241bfa696415bf3581e65,

title = "Failure of chemotherapy to prolong life in patients with metastatic prostate cancer who have failed androgen deprivation",

abstract = "Using historical controls, we analyzed the effect of chemotherapy on survival of patients with metastatic prostate cancer who failed androgen deprivation. The survival of 178 patients with metastatic prostate cancer who receive palliation only after failing hormonal therapy was compared with the survival of 27 patients who received chemotherapy on NPCP Protocol 1500. Survival was measured from the initiation of androgen deprivation. The mean survival after chemotherapy was 8.4 months which was slightly less than the group receiving palliation only. At this time, chemotherapy has not been able to improve survival in patients with metastatic prostate cancer.",

author = "David Hickey and John Cant and Soloway, {Mark S.}",

year = "1988",

month = jan,

doi = "10.1016/0090-4295(88)90569-9",

language = "English (US)",

volume = "31",

pages = "38--40",

journal = "Urology",

issn = "0090-4295",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - Failure of chemotherapy to prolong life in patients with metastatic prostate cancer who have failed androgen deprivation

AU - Hickey, David

AU - Cant, John

AU - Soloway, Mark S.

PY - 1988/1

Y1 - 1988/1

N2 - Using historical controls, we analyzed the effect of chemotherapy on survival of patients with metastatic prostate cancer who failed androgen deprivation. The survival of 178 patients with metastatic prostate cancer who receive palliation only after failing hormonal therapy was compared with the survival of 27 patients who received chemotherapy on NPCP Protocol 1500. Survival was measured from the initiation of androgen deprivation. The mean survival after chemotherapy was 8.4 months which was slightly less than the group receiving palliation only. At this time, chemotherapy has not been able to improve survival in patients with metastatic prostate cancer.

AB - Using historical controls, we analyzed the effect of chemotherapy on survival of patients with metastatic prostate cancer who failed androgen deprivation. The survival of 178 patients with metastatic prostate cancer who receive palliation only after failing hormonal therapy was compared with the survival of 27 patients who received chemotherapy on NPCP Protocol 1500. Survival was measured from the initiation of androgen deprivation. The mean survival after chemotherapy was 8.4 months which was slightly less than the group receiving palliation only. At this time, chemotherapy has not been able to improve survival in patients with metastatic prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=0023849507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023849507&partnerID=8YFLogxK

U2 - 10.1016/0090-4295(88)90569-9

DO - 10.1016/0090-4295(88)90569-9

M3 - Article

C2 - 2447693

AN - SCOPUS:0023849507

VL - 31

SP - 38

EP - 40

JO - Urology

JF - Urology

SN - 0090-4295

IS - 1

ER -